J Clin Oncol
Pooled cord blood cells boost survival, eliminate severe GVHD in early transplant trial
Clinical takeaway: Consider that adding nonengrafting expanded progenitor cells to single-unit cord blood transplantation may accelerate recovery and dramatically reduce severe GVHD risk, though larger trials are needed before routine adoption.
Cord blood transplantation is often limited by low cell dose and delayed engraftment; this novel pooled-cell strategy could expand access while reducing life-threatening complications.
A phase 2 study in 28 patients with hematologic malignancies suggests that adding a pooled, expanded progenitor cell product (dilanubicel) to single-unit cord blood transplantation is both safe and associated with striking clinical outcomes.
At a median follow-up of ~1.4 years, 27 of 28 patients (96%) were alive and disease-free, with only one non-relapse death and one relapse successfully treated. Notably, no patients developed grade 3 to 4 acute or chronic graft-versus-host disease (GVHD), a major cause of morbidity and mortality in allogeneic transplant.
All patients achieved neutrophil engraftment (median, 18 days) and platelet recovery (median, 31 days), with early hematopoietic support driven by the pooled product, which peaked around day 7 and disappeared by day 14. This transient support appeared to facilitate durable engraftment from the primary cord blood unit while avoiding long-term donor persistence.
The investigational product combines stem cells from 6 to 8 cord blood donors expanded ex vivo, addressing the longstanding limitation of insufficient cell dose in single-unit transplants. Compared with historical controls, the approach showed faster hematopoietic recovery and markedly lower severe GVHD rates.
“This is the first time transplant patients received cells from what amounts to nine different human beings,” said lead author Filippo Milano, MD, PhD, highlighting the novel pooled-donor strategy.
While promising, the authors emphasize that these results require confirmation in larger studies before widespread clinical use.
Source: Milano F, et al. (2026, April 27). J Clin Oncol. Safety and Clinical Outcomes of Pooled Donor, Nonengrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation